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Abstract 
Background: Mesenchymal Stem Cells (MSC) have ability to regulate 
immune response via proinflamatory cytokines. In this study we aimed 
to investigate the effect of different mechanism for T cell activation and 
adjacency on immunoregulatory properties of MSC.   
Methods: Bone marrow MSCs were purchased and T cells were 
obtained from whole blood sample. T cells were activated by two 
different mechanisms using Peripheral Blood Mononuclear Cell 
(PBMC) and phytohemagglutinin (PHA) and then co-cultured with 
MSC using transwell cultures (Indirect contact) and usual plate (Direct 
contact). After 96 hours TGF-b concentration in culture medium and 
indole amine 2, 3-dioxygenase (IDO) activity in cell lysate were 
assayed. We used ANOVA and T-test for statistical analysis and 0.05 
was considered as significant level. 
Results: Our result showed a significant increase of TGF-b secretion 
and IDO activity. Increase in mixed lymphocyte culture (MLC) groups 
was more significant than lymphocyte transformation test (LTT) in 
compare with control. 
Conclusions: The present study confirmed immunoregulatory effect of 
BM-MSC. Also this study showed that MLC of BM-MSCs and T cells 
have more immunoregulatory effects than LTT.  
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Introduction 
Mesenchymal stem cells (MSCs) are found in nearly all 
tissues of body. MSCs have the potential for self-renewal and 
differentiating into several cell types. Also in experimental and 
physiological conditions, MSCs can differentiate into 
specialized cells.1,2 there is hope that Stem cells can be used for 
the treatment of many diseases using cell therapy.3,4 
MSCs can be obtained from nervous and adipose tissues, 
bone marrow etc. These cells have a fibroblastic appearance 
with self-renewal capacity, MSCs can be passaged many times 
without significant change of distinct properties.5 Recently, 
researchers have shown that MSCs have an ability to inhibit 
immune system activity licensed by inflammatory 
environment.6 This property is due to the proinflamatory 
cytokines such as  interferon gamma (IFN-γ), tumor necrosis 
factor alpha (TNF-α), interleukin-1 alpha and beta (IL-1) α,β 
which can stimulate MSCs to elicit very high levels of 
immunosuppressive factors such as CXCR3 ligand, CCR5 
ligand, ICAM1and VCAM1.7 
We also showed in our pervious study that PBMSC can act 
as an immune modulator factor via the IL-2 and IFN-γ.8,9 
Mechanism and molecules which mediate MSC-induced 
immunosuppressive effects are not the same in different 
species. As an example, iNOs are lightly immunosuppressive at 
high concentration via undefined pathway in murine model but 
in human model IDOs are like this.3,10
 
In factin response to 
IFN-γ, MSCs express the major KP enzyme IDO,11 so they can 
inhibit T cell proliferation and regulate the function of main 
cell populations in both adaptive and innate immune systems, 
including natural killer cells, antigen presenting cells, T- and 
B-cells.12 Moreover, IFN-γ-induced activation of IDO in MSCs 
can create a Tryptophan-depleted milieu which give promotion 
to immunosuppression.13 IDO is the first and rate-limiting 
enzyme in the metabolism of tryptophan. It is produced by 
many cell types including macrophages, dendritic cells, human 
MSCs, and most tumor cells,.14 IDO suppresses immune 
responses severely by decrease of local tryptophan and increase 
of accumulation of tryptophan metabolites including quinolinic 
acid, 3-hydroxyanthranillic acid and kynurenine.3 However, the 
actual molecular mechanisms of IDO immunosuppressive 
function and its overall role in the immune response remain 
extensively unknown.3,15 
Family of TGF-b molecules are pleiotropic cytokines with 
important roles in growth, wound healing immunoregulation 
and cancer.15 Three TGF-b isoforms TGF-b1, TGF-b2, and 
TGF-b3 have been detailed in mammalian species. TGF-b1, the 
prototype of this family, is a renowned immunosuppressive 
molecule.16 Interestingly, TGF-b1 is responsible for MSC-
dependent inhibition of T cells proliferation.17,18 
MSCs modulate immune response via interaction with a 
diversity of immune cells including dendritic cells, T and B 
lymphocytes and NK cells using this mechanism. However it is 
still unclear that cell to cell contact is necessary for starting this 
mechanism or only environmental cytokines are adequate.19,20
 
In this study, we aimed to investigate whether cell to cell 
contact is necessary for immunosuppressive effects of Bone 
Marrow MSCs (BM-MSCs) using different activated T-cells. 
Materials and Methods 
Protocols and method were performed according our 
previous study.8,9 
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Human BM-MSCs were purchased as a 70% confluent T75 
cell culture flask (Passage 3) from Isfahan Royan Institute. In 
order to achieve required number of cells for the study, BM-
MSCs were expanded in vitro. Purchased cells were 
immediately cultured in complete DMEM (Gibco, Canada) and 
10%FBS (Gibco, Canada). Every two days, cell medium was 
changed. After 4-5 days cells were detached by trypsin/EDTA 
solution (Sigma, USA) and again cultured in three flasks. This 
process was repeated until BM-MSCs got to passage 5 and also 
adequate count for further co-culture with activated T cells 
lymphocyte. The cell counting and their viability determination 
by trypan blue stain were done as standard procedures.21 All of 
the culture processes were don in Isfahan University of 
Medical Sciences.  
Five to 15 ml (Depending on the number of co-cultures) 
heparinized venous blood samples were taken from a healthy 
person (sample 1) and another healthy allogeneic volunteer 
(Sample 2). 
Isolation of T cell from sample 1: 50μ  of RosetteSep® 
Human T Cell Enrichment Cocktail was added to every 1mL of 
whole blood and mixed well (was incubated 20 minutes at 
room temperature).The blood was diluted with an equal volume 
of PBS+2% FBS and mixed gently. The diluted sample was 
layered on top of appropriate amount of Ficoll and they were 
centrifuged for 20 minutes at 2500 rpm at room temperature, 
with the brake off. After that, the enriched T cells were 
removed from the Ficoll plasma interface, they were washed 
with PBS+2% FBS (twice) and were suspended in culture 
medium.T cell suspension was adjusted at 2×106 Cells/ml. 
Isolation of PBMC from sample 2: 5 ml whole blood 
diluted with an equal volume of PBS, was gently overlaid on 
top of 5 ml Ficoll Hypaque and was spined at 2500 rpm for 20 
min at RT. The mononuclear cell layer was collected from 
interphase of PBS/ Ficoll with a sterile pipette and transferred 
to a new tube. The cells were washed once with PBS (1500 
rpm, 10 min) and they were resuspended in RPMI. The cell 
suspension was adjusted at 2 × 106 viable cells/ml. 
Mitomycin treatment of cells:  
1- Inactivation of BM-MSC: BM-MSCs were trypsinized, 
counted and the suspension of 2 ×106 viable cells/ml in DMEM 
medium was prepared and 7μl of Mitomycin stock solution was 
added to BM-MSC suspension (so final concentration of MMC 
was 7µg/ml). After 3 hours (in 37  c), BM-MSCs were washed 
three times by PBS. This suspension (adjusted to 1 × 105 viable 
cells/ml in completed medium) was prepared for use in co-
cultures. 
2- Inactivation of stimulator cells: The final concentration 
of MMC in the cell suspension of PBMCs was adjusted at 
20µg/ml. The suspension was set in the incubator for 30 min. 
Then cells were washed with PBS three times. Again a cell 
suspension of 2 × 106 viable cells/ml was prepared and used to 
stimulate T cells in MLC co-cultures. 
Co-cultures: 
1- Direct co-cultures (in usual plate): Mixed Lymphocyte 
Culture (MLC): Inactivated BM-MSC + T cell + Inactivated 
PBMC 
At first, to six four-well sets of flat-bottom of 96 well cell 
culture plates, 100 µl, 40 µl, 20 µl and 10 µl of BM-MSC 
suspension were added respectively. The volume of cell 
cultures in all wells was made up to 100 µl with RPMI 
(completed medium), No BM-MSC was added in four wells 
(only RPMI 100 µl was added). 
The stem cells were allowed to adhere for 18- 20 hours 
incubation in 37˚C0, 5% CO2. After this time ,one set of  four- 
wells were used as control, so no lymphocytes were added 
.another set of  four- well  was chosen for mMlc so only T cells 
(50 µl) were added to BM-MSC. In another set of four- wells 
that remained, 50 µl of T cell suspension and 50 µl of 
stimulator cell suspension (both prepared a few hour before the 
use as mentioned in below) were added. 
In the first set, any kind of antibody was added. A 
neutralizing anti-human TGF-β1 mAb (at concentration of 5 
μg/ m ) was added to second set of four-well. In the third set 
anti-human TGF-β1 mAb (at concentration 50 μg/ m ) was 
added. A neutralizing anti-human IFNγ mAb (at concentration 
5 μg/m ) was added to the fourth set. Only T cell and PBMC, 
(as a negative control) separately were added to wells 
contained culture medium. Also culture medium was as a 
negative control).Fifty µl of T cell suspension and 50 µl of 
stimulator cell suspension (PBMC) were added to another well 
with 100 µl of culture medium alone (positive control. All 
cultures were done in duplicate. The experiments were 
performed at least 3 times.22 The plate was incubated for 96 
hour in the incubator.23 
Lymphocyte Transformation Test (LTT): In these cultures, 
phytohemagglutinin (PHA; 4 μg/m ) was used instead of 
PBMC to induce T-cell proliferation. One hundred µl, 40 µl, 20 
µl and 10 µl of BM-MSC suspension were added to four-well 
set of a flat-bottom of 96 well cell culture plate, respectively. 
(One of four-well sets was used as control, so no lymphocytes 
were added. With RPMI (completed medium), the volume of 
cell cultures in all wells were made up to 100 µl. Additionally, 
to three extra wells, only 100 µl of RPMI (completed medium) 
were added. The stem cells were allowed to adhere for 18-20 
hour incubation in 37˚C, CO2 incubator. 
After this time, T cell suspension (prepared at few hour 
before the use) was diluted with culture medium to obtain the 
concentration of 106 cells/ml. Amount of 100 µl of this 
suspension was added to a well contained only 100 µl of 
culture medium negative control. Then, with PHA stock 
solution, the final concentration of PHA in T cell suspension 
was adjusted at 8 µg/ml. One hundred µl of T cell suspension 
plus PHA were added to four sets of four -wells contained 
decreasing amount of BM-MSC (like MLC any antibody was 
added to one of sets but neutralizing anti-human TGF-β1 mAb 
and IFNγ mAb were added at another set of four- wells, 
seperately) and a well contained only culture medium. Another 
one was LTT for positive control. Another four-well set was 
added 100 µl of culture medium, alone. At  the end ,the volume 
of all wells were made up to 200 µl  with culture medium .The 
plate was incubated for 72 hour in 37˚C, CO2 incubator. 
2- Transwell cultures (indirect co-culture): Transwell 
chambers with a 0.3 μm pore size membrane were used to 
separate the lymphocytes and stimulators from the BM-MSC. 
Lymphocytes were co-cultured with inactived PBMC or PHA, 
whereas BM-MSCs were placed in inner transwell chamber.  
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The details of doing co-cultures were the same as direct co-
cultures, expect that all volumes were increased by 2.5 times. 
Measurement of TFG- β1 produced by BM-MSC: Levels 
of transforming growth factor (TGF)-β1 in BM-MSC culture 
medium were measured by colorimetric enzyme linked 
immunoassays according to the manufacturer’s instructions. 
(Quantikine® ELISA Human TGF-β1 Immunoassay, R&D 
Systems, Inc.USA). 
Statistical analysis was performed by  the SPSS software 
and univariate analyse of variance and independent T-test were 
used to analyze the significance of  the mean difference of 
proliferation between groups. P less than 0.05 was considered 
to be statistically significant. 
Results  
The phenotype of BM-MSC was determined previously by 
flowcytometery (positive for CD44, CD90, CD29 (stem cell 
marker) and negative for CD14, CD45and CD34 
(hematopoietic marker).  
The secretion of TGF-β1 was elevated when MSCs were 
cultured with MLR and LTT. We detected immunosuppressive 
cytokines such as TGF-β1 in MSC-conditioned medium. TGF-
β1 secretion was elevated when co-cultured BM-MSCs with T 
lymphocytes stimulated with PBMC or PHA compared with 
BMSCs single-cultured group. In all ratios, the levels of TGF-
β1 was statistically significant (P˂0.05) (Data were shown in 
Table 1 and Figure 1). 
The differences between levels of TGF-β1 secretion in co-
cultured BM-MSCs with LTT were not statistically significant 
in comparison with co-cultured BM-MSCs with MLR. The 
differences between levels of TGF-β1 secretion in co-cultured 
BM-MSCs with LTT were statistically significant compared 
with single-cultured group (only BM-MSC, P˂0.05). The same 
results were obtained in co- coultures of BM-MSCs with MLC 
comparing with only BM-MSCs (P˂0.05). 
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Figure 1. The levels of TGF-β1 secretion in co-cultured BM-MSCs with T lymphocytes stimulated with PBMC compared with T lymphocytes stimulated with PHA 
Discussion 
Even though it has been widely substantiated that MSCs 
have potent immunoregulatory functions in vitro and vivo its 
mechanisms of suppressing alloresponses are not completely 
understood. This study, explored the role of cell-contact-
dependent mechanisms using MLR and LTT models and 
clarified the contribution of BM-MSC immunosuppressive 
milieu through cytokine secretion. 
A number of studies have suggested that the inhibitory 
effects of BM-MSCs are mediated by soluble factors, 
particularly TGF-β1.15,24 To determine the accuracy of this 
under our conditions, we cultivated purified human T cells with 
BM-MSCs at the indicated ratios, in the presence or absence of 
different dosage of TGF-β1 neutralizing antibody (5μg/ml and 
50 μg/ml).  
We found that TGF-β1 neutralizing antibody abrogated the 
inhibitory effect of BM-MSCs on T cells to some extent, 
however not thoroughly. Addition of anti- TGF-β1 blocking 
antibody had better influence on reduction of inhibitory activity 
when used at 10-fold higher concentrations (50μg/m ). These 
Table 1. The levels of TGF-β1 secretion in co-cultured BMSCs with T lymphocytes stimulated with 
PBMC or PHA compared with BM-MSCs single-cultured group 
BM-MSC/T Cell Ratio 
TGF-β1(ρg/ml) 
T MLC LTT Only BM-MSC P 
1/100 _ 5.57 ± 0.31 5.01 ± 0.27 2.36 ± 0.07 <0.001* 
1/50 _ 6.07 ± 0.32 5.87 ± 0.26 3.53 ± 0.12 <0.001* 
1/25 _ 7.73 ± 0.29 7.01 ± 0.27 4.67 ± 0.10 <0.001* 
1/10 _ 9.15 ± 0.30 8.90 ± 0.33 6.46 ±  0.5 <0.001* 
None 0.71± 0.02 1.73 ± 0.20 1.53 ± .022 _  
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data support the assumption that TGF- β1plays a major role in 
MSC-mediated inhibitory activity.  
Mauro Krampera et al. suggested that 1μg/m  of TGF-β1 
neutralizing antibody had no influence on inhibitory activity of 
BMSC even when used at concentration 10-fold higher (10 
μg/m ).25 
Di Nicola et al showed that the induced suppression of 
responder T cells by human MSCs against stimulator PBMCs 
could be abrogated by high concentrations of neutralizing 
antibodies versus hepatocyte growth factor (HGF) and TGF-β1. 
Blocking of each factor separately resulted in a minimal effect 
on suppression, inasmuch as neutralization of the cytokines 
simultaneously restored all proliferation of T cells.26 
 These studies may not be similar with our study because 
Di Nicola26 and co-workers used blocking antibody in lower 
dosage and Krampera26 worked in another Species (mice) 
which could explain these different findings. 
Also in this study, the levels of TGF-β1 were determined in 
the conditioned media of T cell, MLR and LTT, both in the 
BM-MSCs cultured alone or presence/absence of BM-MSCs. 
TGF-β1was detected in conditioned media of both BM-MSCs 
and immune cells. Results indicated that the TGF-β1 secretion 
was elevated when co-cultured BMSCs with T lymphocytes, 
compared with BMSCs single-cultured group, indicating that 
the interaction of immune cells with BM-MSCs result in 
increased TGF-β1secretion. 
This work emphasizes that effect of superior inflammatory 
cytokines at the site of transplantation and anti-inflammatory 
cytokines secreted by MSC should be considered for accessing 
the immunomodulatory behavior of these cells in different 
clinical settings. Tissue damage and inflammation are co-
localized processes and coincident. Hence it is not unexpected 
that MSC can be activated by inflammatory signals and such 
activation should support up-regulation of potent 
immunomodulatory activity. Therefore the current study 
reinforces the potential useage of MSCs in the clinical setting 
for inflammation characteristic. 
In the current study, we confirmed which human MSC via 
the action of TGF-b upregulated the intracellular enzyme of 
IDO and so inhibition of IDO activity resulted in a whole 
abrogation of the immunosuppressive effect of MSC on T cells. 
In our previous study we showed that MSCs can inhibit T cell 
proliferation by increasing of IFNγ and I -2.8,9 
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